Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Cancer Discov. 2021 Mar 16;11(8):2032–2049. doi: 10.1158/2159-8290.CD-20-0242

Figure 2: CD72 is a highly-abundant cell surface marker upregulated on the MLLr cell surface.

Figure 2:

(a) Schematic showing triage of cell surface membrane proteins to identify immunotherapy candidates for MLLr B-ALL. (b) Flow cytometry histograms of CD72 and CD19 surface density on MLLr B-ALL patient-derived xenografts and cell lines. Molecules of receptor per cell were calculated using a quantitative flow cytometry assay. (c) Representative flow cytometry histograms of CD72 surface density on viably-frozen, pediatric B-ALL patient samples. Log2 of the Median Fluorescence Intensity (MFI) of CD72 staining is graphed on the y-axis, comparing MLLr to non-MLLr patient samples on the x-axis (total, n =11) (d) Quantification of CD72 abundance by immunohistochemistry (IHC) staining of banked adult B-ALL patient bone marrow aspirates (total, n =15). Each tumor was graded for staining percentage and intensity by two independent pathologists blinded to sample identity, which were used to calculate IHC H-scores (range: 0-300). (e) Representative raw images of CD72 staining intensity by IHC of two different B-ALL subtypes. See also Supplementary Fig. S3, S4, and S5.